The Role of Budesonide in Adults and Children with Mild‐to‐Moderate Persistent Asthma
Authors:
- 1 January 2004
- journal article
- review article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 41 (1) , 5-17
Abstract
Asthma, a chronic and potentially life‐threatening disease of the airways, affects patients of all ages. Inhaled corticosteroids (ICS) are the recommended first‐line therapy for patients with persistent asthma. To review the clinical efficacy and tolerability data available on budesonide in the treatment of mild‐to‐moderate persistent asthma, a MEDLINE database search was performed for 1996–2003 using the following key words: budesonide, inhaled corticosteroid, efficacy, safety, systemic. When administered once or twice daily, budesonide effectively controls asthma in children, adolescents, and adults with mild‐to‐moderate asthma. Budesonide can be delivered effectively via a dry powder inhaler (Pulmicort Turbuhaler®) in patients aged ≥ 6 years or as an inhalation suspension (Pulmicort Respules®) in children as young as 12 months. With over 20 years' clinical exposure, budesonide has been demonstrated to be well tolerated in the treatment of chronic asthma in patients as young as 12 months. Specifically, at doses required to treat mild or moderate persistent asthma, budesonide does not affect hypothalamic‐pituitary‐adrenal axis function, bone mineral density, cataract formation, or final adult height. As Pulmicort Turbuhaler®, budesonide is the only ICS to achieve a Food and Drug Administration pregnancy category B rating. Early intervention with budesonide is recommended in asthma management: maximum benefit from therapy is reported in patients treated within 2 years of disease recognition. Budesonide is effective and well tolerated in the control of mild‐to‐moderate persistent asthma in patients aged 12 months and older. There is no evidence for variation in efficacy in population subgroups.Keywords
This publication has 72 references indexed in Scilit:
- Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroidsAnnals of Allergy, Asthma & Immunology, 2001
- Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthmaAnnals of Allergy, Asthma & Immunology, 2001
- Association between intraocular pressure and budesonide inhalation therapy in asthmatic patientsAnnals of Allergy, Asthma & Immunology, 2000
- Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young childrenAnnals of Allergy, Asthma & Immunology, 1999
- Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Once-Daily Inhaled Corticosteroids in Children with AsthmaDrugs, 1999
- Once-Daily Inhaled Corticosteroids in Mild to Moderate AsthmaDrugs, 1999
- Adverse effects of inhaled budesonide (800 μg) on growth and collagen turnover in children with asthma: A double-blind comparison of once-daily versus twice-daily administrationThe Journal of Pediatrics, 1998
- Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1998
- Bone metabolism in children with asthmatreated with inhaled beclomethasone dipropionateThe Journal of Pediatrics, 1993